Risk of type 1 diabetes climbs when one population of T cells falls

April 5, 2018, Joslin Diabetes Center
Stephan Kissler, Ph.D., Investigator in the Section on Immunobiology at Joslin Diabeates Center, and Assistant Professor of Medicine at Harvard Medical School. Credit: Stephanie M. McPherson

In autoimmune diseases such as type 1 diabetes, some of the immune system's T cells mistakenly attack the body's own cells, while protective T regulatory cells try to defend against that attack. Scientists at Joslin Diabetes Center have shown in a mouse model of type 1 diabetes that animals with fewer of a poorly studied type of T regulatory cells are much more likely to develop the disease.

Most T develop and mature in the thymus, a small lymphatic organ above the heart, says Stephan Kissler, Ph.D., an Investigator in Joslin's Section on Immunobiology. But a small population of these cells known as peripherally induced T regulatory (pTreg) cells instead forms outside the thymus.

"We are the first to demonstrate that these pTregs are important in autoimmune ," says Kissler, who is senior author on a report in the European Journal of Immunology and Assistant Professor of Medicine at Harvard Medical School.

The researchers now hypothesize that microbes in the gut, where most of this pTreg cell is switched on, may be responsible for generating these protective cells and thus protecting against the autoimmune attack on that cause type 1 diabetes.

"Most of these pTregs are made in the gut," Kissler says. "We know both that gut microbes promote the development of pTregs, and that gut microbes have an impact on type 1 diabetes." Many studies in mouse models, and more recent research among human populations as well, have correlated differences in gut microbe populations with risks of developing the autoimmune condition.

As Kissler's lab began to examine whether pTregs play a role in diabetes, the scientists first looked for these cells in the non-obese diabetes (NOD) of type 1 diabetes. The researchers found that pTregs were present in the pancreas and in the pancreatic lymph node, which is close to the gut as well as the pancreas, and is the major site where autoreactive T cells are triggered to launch the attack on the pancreas. This finding suggested that pTregs might defend against this autoreactive attack.

Next, the researchers created NOD mice that were modified with CRISPR/Cas9 genome editing tools to remove one genetic region that is needed to produce pTregs. The resulting mice had normal populations of T regulatory cells from the thymus, but significantly diminished numbers of pTregs.

These mice generally appeared similar to normal NOD mice—with the one big exception that they were far more prone to develop , Kissler says.

The next step for his lab will be to test the hypothesis that these protective pTregs in diabetes are dependent on gut microbes, and that this mechanism could explain the influence of gut on type 1 diabetes risk.

The researchers will take advantage of Joslin's recently created facility for studying germ-free animals, testing various sets of bacteria among germ-free mice to find out which bacteria may boost or depress populations of pTregs while also modifying the risk of diabetes.

Clinical trials are now underway that aim to see if the large populations of T regulatory cells generated in the thymus can be exploited to better protect against type 1 diabetes. While pTreg research is still at an early stage, better understanding of these cells may eventually point toward potential drug candidates, Kissler suggests. "If we find that these are induced by bacteria, and then find which bacterial products affect that process, we might be able to bypass the complexity of changing the and instead intervene directly to increase the pTregs," he says.

Explore further: Could modifying gut microbes prevent or delay type 1 diabetes?

Related Stories

Could modifying gut microbes prevent or delay type 1 diabetes?

September 12, 2017
Autoimmune diseases such as type 1 diabetes are controlled by our genes. While researchers are eager to find out what other factors could contribute to this disease, a new study published by Yale researchers provides direct ...

Solving a genetic mystery in type 1 diabetes

April 11, 2016
In type 1 diabetes, the immune system attacks the body's own insulin-producing cells. Scientists understand reasonably well how this autoimmune attack progresses, but they don't understand what triggers the attack or how ...

Researchers increase understanding of genetic risk factor for type 1 diabetes

November 28, 2012
As part of their ongoing research on the role of genes in the development of type 1 diabetes, Joslin Diabetes Center scientists, in collaboration with scientists at the University of Würzburg, have demonstrated how a genetic ...

Discovery provides insight into development of autoimmunity

May 12, 2015
Joslin researchers have uncovered the action of a gene that regulates the education of T cells, providing insight into how and why the immune system begins mistaking the body's own tissues for targets. The gene, Clec16a, ...

How gut microbes may trigger type 1 diabetes

September 13, 2016
Research on the tiny microbes that live in our gut has yielded clues to understanding a growing number of medical conditions. A new Yale-led study explores the link between gut microbes and type 1 diabetes.

Scientists study how some insulin-producing cells survive in type 1 diabetes

February 9, 2017
A Yale-led research team identified how insulin-producing cells that are typically destroyed in type 1 diabetes can change in order to survive immune attack. The finding may lead to strategies for recovering these cells in ...

Recommended for you

Switching to certain antidiabetic drugs linked to increased risk of major complications

July 18, 2018
For people with type 2 diabetes, switching to sulfonylurea drugs to control blood sugar levels is associated with an increased risk of complications compared with staying on the drug metformin, finds a study in The BMJ today.

Researchers cure type 2 diabetes and obesity in mice using gene therapy

July 10, 2018
A research team from the UAB led by Professor Fatima Bosch has managed to cure obesity and type 2 diabetes in mice using gene therapy.

Human clinical trial reveals verapamil as an effective type 1 diabetes therapy

July 9, 2018
Researchers at the University of Alabama at Birmingham Comprehensive Diabetes Center have discovered a safe and effective novel therapy to reduce insulin requirements and hypoglycemic episodes in adult subjects with recent ...

New targets found to reduce blood vessel damage in diabetes

July 9, 2018
In diabetes, both the tightly woven endothelial cells that line our blood vessels and the powerhouses that drive those cells start to come apart as early steps in the destruction of our vasculature.

Insurance gaps linked to five-fold rise in hospital stays for adults with type 1 diabetes

July 9, 2018
For a million American adults, living with type 1 diabetes means a constant need for insulin medication, blood sugar testing supplies and specialized care, to keep them healthy and prevent a crisis that could end up in an ...

Abnormal branched-chain amino acid breakdown may raise diabetes risk

July 5, 2018
In the U.S., about five out of 100 expectant mothers develop gestational diabetes mellitus (GDM), a temporary form of diabetes in which hormonal changes disrupt insulin function. Although GDM is often symptomless and subsides ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.